Exane Derivatives’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Exane Derivatives’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Hold	0	–	–	–	694
2016 Q3	–	Hold	0	–	–	–	666
2016 Q2	–	Hold	0	–	–	–	654
2016 Q1	–	Hold	0	–	–	–	587
2015 Q4	–	Hold	0	–	–	–	499
2015 Q3	–	Sell	-30	Closed	-$518	–	530
2015 Q2	$596	Hold	30	–	–	﹤0.01%	455
2015 Q1	$567	Hold	30	–	–	﹤0.01%	458
2014 Q4	$700	Buy	+30	New	+$694	﹤0.01%	482

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Exane Derivatives's CTIC Position: Q4 2016 in Review

Exane Derivatives held its CTI BioPharma Corp. (DE) Common Stock (CTIC) position steady in Q4 2016 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #694.

Exane Derivatives first reported a position in CTIC in Q4 2014 and has held it in 3 quarters since. The position peaked at $700 in Q4 2014. 58 funds tracked by Wall St. Rank hold CTIC as of Q4 2016.

Exane Derivatives held 0 shares of CTI BioPharma Corp. (DE) Common Stock worth $0 as of Q4 2016.
Exane Derivatives left its CTI BioPharma Corp. (DE) Common Stock share count unchanged in Q4 2016.
CTI BioPharma Corp. (DE) Common Stock made up ﹤0.01% of Exane Derivatives's portfolio in Q4 2016, its #694 holding.
Exane Derivatives first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2014 and has held it in 3 quarters since.
Exane Derivatives's CTI BioPharma Corp. (DE) Common Stock position peaked at $700 in Q4 2014.
58 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2016.

Based on Exane Derivatives's 13F filing for Q4 2016, filed 27 Jan 2017.